Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)
15 oct. 2020 17h30 HE
|
Medicenna Therapeutics Corp.
- After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm - - The design sets a new...
Dr. Jack Geltosky Elected to Medicenna Board of Directors
30 sept. 2020 16h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at Upcoming Investor Conferences in September
09 sept. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Commence Trading on Nasdaq
20 août 2020 16h40 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights
04 août 2020 07h30 HE
|
Medicenna Therapeutics Corp.
- Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 - EOP2 meeting scheduled for 29th September, 2020 with FDA input...